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Plakoglobin (γ-catenin) is a member of the Armadillo family of proteins and a homolog of β-catenin. As a component of both the
adherensjunctionsanddesmosomes,plakoglobinplaysapivotalroleintheregulationofcell-celladhesion.Furthermore,similarto
β-catenin, plakoglobin is capable of participating in cell signaling. However, unlike β-catenin that has well-documented oncogenic
potential through its involvement in the Wnt signaling pathway, plakoglobin generally acts as a tumor/metastasis suppressor. The
exact roles that plakoglobin plays during tumorigenesis and metastasis are not clear; however, recent evidence suggests that it
may regulate gene expression, cell proliferation, apoptosis, invasion, and migration. In this paper, we describe plakoglobin, its
discovery and characterization, its role in regulating cell-cell adhesion, and its signaling capabilities in regulation of tumorigenesis
and metastasis.
1.Introduction
Plakoglobin (also known as γ-catenin) is a member of the
Armadillo family of proteins and a structural and functional
homolog of β-catenin. These catenin proteins have two
major roles in the cell: the mediation of cell-cell adhesion
and cell signaling. As adhesive proteins, both β-catenin
and plakoglobin interact with the cytoplasmic domain of
cadherins, thereby tethering the cadherin proteins to the
cytoskeleton. In addition to their cell-cell adhesive functions,
both β-catenin and plakoglobin interact with a number
of intracellular partners including signaling proteins and
transcription factors, which accounts for their involvement
in cellular signaling [1–4]. Despite these similarities, a major
diﬀerence between β-catenin and plakoglobin emerges when
considering their signaling functions. While β-catenin has a
well-deﬁned oncogenic potential as the terminal component
of the Wnt signaling pathway [5–7], plakoglobin is typically
associated with tumor/metastasis suppressor activity [8–10].
However, the mechanisms that underlie this activity remain
undeﬁned. In this paper, we have focused on the potential
roles of plakoglobin during tumorigenesis and metastasis
in an attempt to deﬁne how this often overlooked protein
contributes to these complex processes.
2. Plakoglobin: InitialIdentiﬁcation and
Early Characterization
Plakoglobin was initially identiﬁed as an 83kDa protein
component of the desmosomal plaque [11]. Subsequently,
using monoclonal antibodies, cDNA cloning, and a com-
bination of biochemical, morphological, and molecular
a p p r o a c h e s ,C o w i ne ta l .[ 12] demonstrated that this 83kDa
protein was present in both desmosomes and the adherens
junction and was given the name plakoglobin.
Although plakoglobin was identiﬁed as a junctional
protein, the role that it played in these junctional complexes
was unclear, and the partners with which plakoglobin
interacted were not identiﬁed. It was not until several
years later that coimmunoprecipitation experiments showed
that plakoglobin interacted with the desmosomal cadherin
desmoglein, thereby conﬁrming plakoglobin as a constituent
of the desmosomes [13]. In addition, several groups showed
that E-cadherin (initially known as uvomorulin) immuno-
precipitates contained three distinct proteins, which became
known as α-, β-, and γ-catenin [14–16]. These studies
showed that these three catenin proteins, with molecular
weights of approximately 102, 88, and 80kDa, respectively,
interacted with the cytoplasmic domain of E-cadherin.2 International Journal of Cell Biology
Further work analyzing the formation and stability of the E-
cadherin-catenin complexes suggested that the E-cadherin-
β-catenin complex was formed immediately after E-cadherin
synthesis and was very stable. Interestingly, these studies
also found that α-catenin could not be found in association
with E-cadherin independent of β-catenin, suggesting that
β-catenin was a physical link between E-cadherin and α-
catenin. However, since γ-catenin was found to be only
loosely associated with E-cadherin, it was determined that
the main adhesive complexes consisted of E-cadherin, β-
catenin, and α-catenin, although the existence of a separate
E-cadherin-γ-catenin complex could not be ruled out [16].
At this time there was some confusion as to the identity
of the catenin proteins and their relationship to plakoglobin.
It soon became evident that plakoglobin was a homolog
of β-catenin, a 92kDa E-cadherin-associated protein [17].
However,itwasnotuntiltheworkofKnudsenandWheelock
[18] that it became clear that the 80kDa protein that was
associated with E-cadherin was indeed plakoglobin. In this
study, the authors showed that plakoglobin interacted with
both E- and N-cadherin and that it was a distinct protein
from β-catenin [18]. This ﬁnding was conﬁrmed by work
from other groups demonstrating that plakoglobin and γ-
catenin were indeed the same protein [1, 19].
Subsequent analysis of the kinetics of plakoglobin syn-
thesisandassociationswithcadherinsdemonstratedthatfol-
lowing synthesis, plakoglobin interacted with both desmo-
glein and E-cadherin in both the soluble and cytoskeleton-
associated pools of cellular proteins. In addition, a dis-
tinct, cadherin-independent pool of plakoglobin was also
observed, suggesting that plakoglobin may have a role in the
cell in addition to cell adhesion. Finally, phosphorylation
experiments revealed that whereas the insoluble (cadherin-
associated) pool of plakoglobin was serine phosphory-
lated, the soluble pool was serine, threonine, and tyrosine
phosphorylated, suggesting that these diﬀerent pools of
plakoglobin are diﬀerentially regulated and perform varying
functions [20]. Collectively, these studies demonstrated that
plakoglobin is a homolog of β-catenin and a unique protein
in that it is the only component common to both E-cadherin
and desmosomal cadherin-containing junctions.
3.Plakoglobin Functions:Cell-CellAdhesion
The most documented role of plakoglobin within the cell is
in cell-cell adhesion. As such, plakoglobin is found in both
adherens junctions and desmosomes (Figure 1). Adherens
junctions are a ubiquitous type of intercellular adhesion
structure present in both epithelial and nonepithelial cells,
whereas desmosomes are adhesive junctions that confer ten-
sile strength and resilience to cells and are present not
only in epithelial cells but also in nonepithelial cells that
endure mechanical stress, such as cardiac muscle. Both
adherens junctions and desmosomes are cadherin based.
Cadherins are single-pass transmembrane glycoproteins that
form homotypic interactions with cadherin proteins on
neighboring cells. Intracellularly, cadherins interact with
proteins of the catenin family. At the adherens junction, the
C-terminal domain of E-cadherin interacts, in a mutually
exclusive manner, with β-catenin or plakoglobin, which then
interacts with α-catenin, which is an actin-binding protein.
A fourth catenin protein, p120-catenin, interacts with the
juxtamembrane domain of E-cadherin and is important for
E-cadherin dimerization and stability at the membrane
(Figure 1;f o rr e v i e w ss e e[ 21, 22]). At the desmosome,
the desmosomal cadherins (desmocollins and desmogleins)
interact intracellularly with plakophilin and plakoglobin,
which interact with desmoplakin, an intermediate ﬁlament
binding protein (Figure 1; for reviews, see [23, 24]).
The identiﬁcation of plakoglobin as a constituent of both
the adherens junction and the desmosomes suggested that it
might play an important role in regulating cell-cell adhesion.
However, the observation that the adherens junctions could
exist as a complex containing E-cadherin, β-catenin, and
α-catenin, independent of plakoglobin [16] questioned the
necessity of plakoglobin, at least at the adherens junctions.
Regardless, it soon became apparent that plakoglobin does
have an essential role in regulating cell-cell adhesion.
It had been previously shown that disruption of E-
cadherin-based cell-cell adhesion led to a transformed
and/or invasive phenotype while reexpression of E-cadherin
in cells lacking its expression resulted in a mesenchymal
to epithelial phenotypic transition [25–31]. Furthermore,
reduced expression of E-cadherin was known to inversely
correlate with the diﬀerentiation grade of tumors [32–37].
WhileitwasclearthattheseE-cadherin-basedjunctionswere
important for the maintenance of an “epithelial” phenotype,
the role of plakoglobin in this phenomenon was not
discerned until it was shown that the expression of E- or P-
cadherin alone in murine spindle cell carcinomas that lacked
endogenous expression of these proteins was not suﬃcient
to modify the morphology or tumorigenicity of these cells
[38]. Although these cadherins were expressed in the cells,
localized to the cell membrane, and interacted with both
α-a n dβ-catenin, they did not interact with plakoglobin.
Further analysis showed that the levels of plakoglobin in
these cells were very low, thus accounting for the absence
of plakoglobin association with E-cadherin. From this work,
the authors suggested that the association of the E-cadherin-
catenin complex with plakoglobin may be necessary for its
tumor suppressing activity.
Another signiﬁcant role for plakoglobin in the regulation
of cell-cell adhesion was discovered when studies showed
that A431 epithelial cells treated with dexamethasone (which
resulted in the isolation of ﬁbroblastic A431 cells lacking
E-cadherin but expressing desmoglein) were unable to
form desmosomes upon exogenous expression of E- or P-
cadherin, despite the formation of the adherens junction
in these cells [39]. Interestingly, the authors observed that
although plakoglobin was present at low levels in these
cells, it was not coimmunoprecipitated with the exogenously
expressed E-cadherin; in fact, the plakoglobin found in
these cells coprecipitated with desmoglein. To examine
the possibility that plakoglobin plays a regulatory role in
desmosomeformation,theauthorsexpressedanE-cadherin-
plakoglobin chimeric protein capable of forming stable
adherens junctions in the cells and observed desmosomeInternational Journal of Cell Biology 3
Intercellular space
Adherens
junction
Cadherin
Cadherin
β-cat α-cat
α-cat
PKP
PKP
Dsg
Dsg
Dsc
Dsc
DP
DP
IF
Desmosome
MF
MF
α-catenin
β-catenin
Plakoglobin
p120-catenin
Plakophilin
Desmoplakin
Cadherin
Desmoglein
Desmocollin
MF, actin microﬁlaments
IF, intermediate ﬁlaments
PG
PG
p120
p120
PG
Figure 1: Cell adhesion complexes in epithelial cells. Cell-cell adhesion is maintained in epithelial tissues by the adherens junction and
desmosomes. At the adherens junctions, E-cadherin forms extracellular interactions with E-cadherin molecules on neighboring cells.
Intracellularly, E-cadherin interacts with either β-catenin or plakoglobin, which then interact with α-catenin, an actin-binding protein. A
fourth catenin, p120-catenin, also interacts with E-cadherin and regulates its stability at the membrane. At the desmosome, the desmosomal
cadherins (desmoglein and desmocollin) interact with plakoglobin and plakophilin, which interact with desmoplakin, which in turn
associates with the intermediate ﬁlament cytoskeleton. The basic, core protein composition of the desmosomes is represented here: the
exact protein constituents of the desmosomes and their interactions vary between diﬀerent types of cells and tissues.
formation. While it had been previously observed that ad-
herens junction formation not only preceded, but was also
a prerequisite for desmosome formation [40–48], this was
the ﬁrst indication that plakoglobin served as a molecule
involved in crosstalk between both junctional complexes in
epithelia.
Following this study, our laboratory demonstrated the
role of plakoglobin in adhesive junction formation by
expressing low/physiological levels of plakoglobin in SCC9
cells, a squamous cell carcinoma cell line that lacks the
expression of both plakoglobin and E-cadherin [9, 49].
Following exogenous plakoglobin expression, SCC9 cells
underwenta mesenchymaltoepidermoid phenotypic transi-
tion that was concurrent with the stabilization of N-cadherin
and the formation of desmosomes and well-organized N-
cadherin-containing adherens junctions [9]. This result con-
ﬁrmed that plakoglobin expression was necessary for desmo-
some formation and also demonstrated that plakoglobin-
N-cadherin interactions could occur prior to desmosome
formation. Other studies have further characterized the
role of plakoglobin in desmosome assembly and function.
Palka and Green [50] demonstrated the role of plakoglobin’s
C terminus for the proper assembly of the desmosomal
plaque, and Acehan et al. showed that plakoglobin is
essential for the eﬃcient binding of desmoplakins to the
intermediate ﬁlaments [51]. Furthermore, plakoglobin was
shown to be necessary for the recruitment of plakophilin
3 to the membrane, desmosome formation, eﬃcient cell-
cell adhesion, and inhibition of cell migration and invasion4 International Journal of Cell Biology
[52, 53]. Finally, work from Birchmeier’s laboratory showed
thatplakoglobindoubleknockoutmicediedduringembryo-
genesis as a result of disrupted heart function due to the
loss of stable desmosomes in the intercalated discs of cardiac
muscle, further conﬁrming the essential role of plakoglobin
in desmosome formation and function [48, 54].
4.Plakoglobin Functions:CellSignaling
4.1. Initial Observations and Controversy. The ﬁrst clue that
plakoglobin might participate in cell signaling came from
studies of the exogenous expression of Wnt-1 in PC12 cells.
Inthesecells,plakoglobinlevelswereincreased,anditunder-
went membrane redistribution, suggesting that, in addi-
tion to β-catenin levels, Wnt-1 can modulate plakoglobin
levels and localization [55]. Subsequently, Karnovsky and
Klymkowsky [56] demonstrated plakoglobin signaling activ-
ity by microinjecting mRNAs-encoding plakoglobin into
fertilized Xenopus embryos, resulting in dorsalized gastrula-
tion and anterior axis duplication. In this study, the exoge-
nously expressed plakoglobin localized both at the plasma
membrane and in punctate nuclear aggregates. Furthermore,
the coinjection of mRNAs-encoding plakoglobin as well
as the cytoplasmic domain of desmoglein suppressed both
dorsalizedgastrulationandanterioraxisduplication.Inthese
embryos, plakoglobin was localized primarily to the plasma
membrane with some perinuclear distribution. These results
suggested that plakoglobin has signaling ability similar to β-
catenin, but when it is sequestered at the plasma membrane
(aspartofdesmosomes),plakoglobinisunabletoparticipate
in cell signaling.
This initial ﬁnding suggested that plakoglobin may have
signaling functions similar to its homologs β-catenin and
the Drosophila Armadillo protein. However, subsequent
studies from various groups have demonstrated that while
plakoglobin does indeed have signaling capabilities, it
appears to function as a tumor suppressor rather than
a tumor promoter. The ﬁrst demonstration of this phe-
nomenon occurred when Simcha et al. [8] found that
plakoglobin expression in SV40-transformed NIH3T3 cells
decreased the ability of these cells to form tumors in syn-
geneic mice. This growth suppressive eﬀect of plakoglobin
was augmented by cotransfection with N-cadherin. The
authors also expressed plakoglobin in the renal carcinoma
cell line KTCTL 60, which lacks endogenous expression of E-
cadherin and desmosomal cadherins, α-catenin, β-catenin,
plakoglobin, and desmoplakin and induces tumor formation
in mice. Plakoglobin expression in KTCTL 60 cells also
inhibited the tumorigenicity of these cells in syngeneic
mice. Notably, the authors showed that the majority of
the plakoglobin in these cells was Triton X-100 soluble,
suggesting that it was not junction associated. This result
was of signiﬁcance because it demonstrated that plakoglobin
could suppress tumor formation independent of its role in
mediating cell-cell adhesion.
These studies made it clear that plakoglobin was capable
of cell signaling and able to act as a tumor suppressor.
Numerous subsequent studies have described the signaling
function of plakoglobin as primarily one of tumor suppres-
sion, although a few reports have suggested that similar to
β-catenin, plakoglobin may have oncogenic activity. In the
following sections, we will present the experimental evidence
for both the tumorigenic and tumor suppressive activities
of plakoglobin and propose possible explanations for these
observed discrepancies.
4.2. Plakoglobin Oncogenic Activity. Kolligs et al. [57]h a v e
shown that the tumor suppressor adenomatous polyposis
coli (APC), which was already known to regulate the levels
of β-catenin, could also regulate plakoglobin protein levels.
In this study, the authors also showed that exogenous
expression of plakoglobin in rat RK3E cells, which express
considerable amounts of endogenous plakoglobin and β-
catenin [57, 58], resulted in a transformed phenotype, which
they suggested was dependent on the upregulation of the
oncogene c-Myc and activation of Tcf/Lef signaling. More
recently, Pan et al. [59] have shown that the exogenous
expression of plakoglobin in HCT116 colon carcinoma cells,
which express a mutant β-catenin protein that cannot be
degraded [60], resulted in genomic instability and increased
invasion and migration.
Both of these studies concluded that plakoglobin pos-
sessed oncogenic activity. However, it must be noted that
several lines of evidence suggest that the oncogenic activity
of plakoglobin may be indirect and achieved through
modulation of the protein levels and signaling ability of β-
catenin [61–67]. Since plakoglobin and β-catenin interact
with some of the same proteins and display high sequence
homology (Figure 2,[ 2, 4, 68, 69]), it became evident that
plakoglobin may, in fact, be able to promote tumorigenesis
by interacting with proteins that would normally sequester
β-catenin (e.g., E-cadherin, Axin, APC), which would result
in increased levels of cytoplasmic and nuclear β-catenin
and in turn enhanced signaling. Indeed, following the
observation that plakoglobin expression resulted in Xenopus
axis duplication [56], the same group showed that this
outcome did not depend on the nuclear localization of
plakoglobin,sincemembrane-anchoredformsofthisprotein
produced the same axis duplication [70]. This demonstrated
that nuclear plakoglobin was inconsequential in inducing
a Wnt-like phenotype, since the cytoplasmic plakoglobin
induced this same phenotype. At the same time, Salomon et
al. [61] showed that overexpression of plakoglobin resulted
in the displacement of β-catenin from, and the increased
association of plakoglobin with, the N-cadherin-containing
adherens junctions. Furthermore, excess cytoplasmic β-
catenin was able to translocate into the nucleus. This was
supported by other work, which showed that overexpression
of plakoglobin in NIH3T3 cells resulted in the nuclear
accumulation of β-catenin and that overexpression of the
Wnt coactivator Lef-1 in MDCK cells resulted in its pref-
erential interaction with β-catenin (instead of plakoglobin).
Subsequently, the β-catenin-Lef complexes were localized to
the nucleus [62], suggesting that when both plakoglobin
and β-catenin were present within the cell, β-catenin-Lef
complexes were more readily formed and transcriptionally
active. Further examination of the ability of plakoglobin toInternational Journal of Cell Biology 5
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Figure 2: Schematic structure of β-catenin and plakoglobin. Both β-catenin and plakoglobin contain 13 Armadillo repeats that are ﬂanked
by N- and C-terminal domains, respectively. The degree of homology between β-catenin and plakoglobin for each Armadillo domain is
indicated. Protein partners that interact with plakoglobin and the domains involved in these interactions are indicated. The corresponding
references are listed in brackets (see [71–76]).
signal via interactions with the Tcf/Lef family of transcrip-
tion factors showed that although plakoglobin interacted
with Lef-1, this complex was ineﬃcient in binding to DNA,
whereas β-catenin-Lef-1 complexes more readily bound
DNA [63]. This study also demonstrated that overexpression
ofplakoglobinresultedinincreasedβ-catenin-Lef-1complex
formation and its association with DNA. Further analysis of
the transactivation potential of β-catenin and plakoglobin
demonstrated that β-catenin was a much stronger activator
of Tcf/Lef target genes than plakoglobin [64].
As mentioned earlier, we have previously shown that
the expression of low/physiological levels of plakoglobin in
plakoglobin-deﬁcient SCC9 cells induced a mesenchymal to
epidermoid change in phenotype, whereas its overexpression
resulted in foci formation and decreased apoptosis, which
was concurrent with the upregulation of the prosurvival
protein Bcl-2 [77]. Using cDNAs-encoding plakoglobin
fused to nuclear localization or nuclear export signals
(NLS and NES), we subsequently showed that Bcl-2 levels
were upregulated in plakoglobin overexpressing SCC9 cells
regardless of plakoglobin localization. Furthermore, in these
cells, β-catenin-N-cadherin interactions were decreased, and
β-catenin accumulated in the nucleus, interacted with Tcf,
and its signaling was increased [65], conﬁrming that the
overexpressed plakoglobin acted indirectly by enhancing the
signaling capability of β-catenin.
The above studies describing the oncogenic potential of
plakoglobin may also be as a result of β-catenin. In Kolligs’s
study [57] where plakoglobin was overexpressed in RK3E
c e l l s( w h i c he x p r e s se n d o g e n o u sβ-catenin and plakoglobin
[58]), it was not determined if plakoglobin could activate c-
Myc expression in the absence of β-catenin or whether either
of these catenins was detected in the nucleus in association
with the c-Myc promoter. In addition, in Pan’s study [59]
in which HCT116 cells showed increased genomic instability
and migration and invasion upon plakoglobin expression,
the endogenous β-catenin was a mutant protein that was
unable to be phosphorylated and subsequently degraded
[60].Whilemuchoftheβ-cateninlocalizedtothemembrane
in these cells [78], plakoglobin expression most likely led to
decreased β-catenin-cadherin interactions and increased β-
cateninsignaling.Insupportofthisprediction,HCT116cells
overexpressing plakoglobin showed increased expression of
the oncogenes securin and c-Myc and decreased expression
of E-cadherin, all of which are documented β-catenin target
genes [79–81]. Taken together, the evidence suggests that
although plakoglobin expression may lead to a transformed
phenotype, it is likely that this outcome is associated
with increased oncogenic β-catenin signaling rather than
oncogenic activity due directly to plakoglobin.
4.3. Plakoglobin Signaling in β-Catenin Null Cells. While the
oncogenic signaling activity of plakoglobin discussed above
can be attributed to the signaling activity of β-catenin rather
than plakoglobin itself, this cannot account for all of the
observations regarding plakoglobin signaling. Recent studies
attempting to discern the signaling activity of plakoglobin
independent of β-catenin have used tissue culture cell lines
that lack the endogenous expression of β-catenin [82–
85]. These studies have shown that in the absence of β-
catenin, plakoglobin does indeed have Tcf/Lef-mediated
transcriptional activity, although this activity is less than
that of β-catenin-Tcf complexes. Interestingly, although
these studies have demonstrated that plakoglobin can signal
through forming transcriptional complexes with Tcf/Lef
transcription factors, they did not assess the tumor-forming
properties of these cells, so it remains unclear as to whether
these cells possessed transformed or nontransformed prop-
erties.Tothatend,ithasbeendemonstratedthatplakoglobin
or β-catenin expression in renal carcinomas lacking endoge-
nous β-catenin and plakoglobin resulted in the upregulation
of Nr-CAM, a neuronal cell adhesion molecule that can
be regulated by both β-catenin and plakoglobin [82].
Furthermore,Nr-CAMexpressioninNIH3T3cellsconferred
a more tumorigenic and invasive phenotype on these
cells. Signiﬁcantly however, although plakoglobin expression6 International Journal of Cell Biology
resulted in increased Nr-CAM levels in renal carcinomas
and although plakoglobin-Tcf/Lef complexes can regulate
Nr-CAM expression, the overall phenotype of these cells
upon plakoglobin expression was nontumorigenic [8]. This
showed that although plakoglobin may regulate β-catenin-
target genes in the absence of β-catenin, it still may suppress
tumorigenesis in the same cells. The homology between
plakoglobin and β-catenin explains the ability of plakoglobin
to signal through Tcf/Lef in the absence of β-catenin. Taken
together, indeed, it is not surprising that if β-catenin is
completely absent from a cell line, plakoglobin cannot only
replace it in junctional complexes, but may also be able to
regulate some β-catenin target genes (e.g., Survivin [85]).
However, as a ﬁnal note, it is important to consider that β-
catenin-null tumors are extremely rare, and in most tumors
and cell lines, plakoglobin signaling activity occurs in the
presence of β-catenin.
4.4. Plakoglobin Tumor Suppressor Activity. Despite the
observation that plakoglobin overexpression promotes tu-
morigenesis mediated by the oncogenic signaling of
β-catenin, several studies examining the signaling function
of plakoglobin have identiﬁed it as a tumor suppressor.
We have previously shown that expression of physiological
levels of plakoglobin in SCC9 cells, which lack endogenous
plakoglobin and E-cadherin, resulted in a mesenchymal to
epidermoid phenotypic transition, which was concurrent
with the stabilization of N-cadherin, the formation of des-
mosomes, and the downregulation of β-catenin [9]. Further-
more, we have found that plakoglobin-expressing SCC9 cells
showed a decreased growth rate compared to parental SCC9
cells. These results, taken together, demonstrated that not
only could plakoglobin act as a tumor suppressor, but that
potentially it does so by decreasing the levels of β-catenin.
The ability of plakoglobin to inhibit cell growth and
proliferation was next observed when Charpentier et al. [10]
expressed plakoglobin (under the control of an epidermal-
speciﬁc promoter) in the basal cells of the epidermis as well
as the hair follicles of transgenic mice. These authors showed
that plakoglobin expression resulted in a reduced prolifera-
tive potential of the epidermal cells and that plakoglobin-
expressing hair follicles had a signiﬁcantly reduced growth
phase, with hairs shorter by roughly 30% after plakoglobin
expression.
Furtherevidencesuggestingagrowthsuppressiveactivity
for plakoglobin was provided in lung cancer, when it was
shown that while β-catenin was uniformly expressed in
various Nonsmall cell lung cancer (NSCLC) cell lines and
lungprimarytumors,plakoglobinexpressionwasverylowor
completely absent [86]. The authors showed that exogenous
expression of plakoglobin in the low-plakoglobin-expressing
NSCLC cells resulted in decreased β-catenin-Tcf signaling,
which was concurrent with decreased cell and anchorage-
independent growth. This result further supported the idea
that plakoglobin can act as a tumor suppressor by inhibiting
the oncogenic activity of β-catenin.
Interestingly, when the authors treated these NSCLC
cell lines with the DNA methylation inhibitor 5-aza-2-
deoxycytidine (AZA) or the histone deacetylase inhibitor
trichostatin A (TSA), plakoglobin levels were increased.
Previous analysis of the plakoglobin promoter had described
CpG islands within the promoter [87], and while it had
been observed that inhibition of DNA methylation could
result in increased plakoglobin protein levels in at least one
thyroid carcinoma cell line [88], this was the ﬁrst indication
thatbothDNAmethylationandhistonedeacetylationplayed
important roles in regulating plakoglobin expression.
The occurrence of methylated CpG islands within the
plakoglobinpromoteraswellashistonedeacetylationhasnot
been limited to NSCLC cell lines. Various groups have shown
that the plakoglobin promoter is methylated in prostate,
bladder, trophoblastic, and mammary carcinomas [89–92],
which is concurrent with a transformed phenotype. Canes et
al.[90]haveshownthattreatmentofbladdercarcinomacells
with TSA resulted in increased plakoglobin expression and a
decreased ability of these cells to form tumors in mice, once
again suggesting a growth inhibitory activity of plakoglobin.
Similarly, when mammary carcinoma cell lines were treated
with AZA, increased plakoglobin levels were observed, as
well as decreased soft agar colony formation and overall cell
growth [92], indicative of decreased tumor-forming ability.
Several lines of evidence suggest that plakoglobin plays
a role in regulating apoptosis, in addition to acting as
a growth suppressor. In their work describing the eﬀects
of plakoglobin on hair growth in transgenic mice, Char-
pentier et al. [10] showed that plakoglobin expression
decreased epithelial proliferation. Moreover, this expression
also resulted in premature apoptosis, because TUNEL assays
showed that the inner root sheath of the plakoglobin-
expressing transgenic follicles underwent apoptosis two days
earlier than in normal hair follicles. In agreement with
these ﬁndings, we have previously shown that SCC9 cells
expressing physiological levels of plakoglobin were more
prone to undergo staurosporine-induced apoptosis when
compared to parental SCC9 cells [77]. We have also observed
that SCC9 cells expressing plakoglobin exclusively in the
nucleus (SCC9-PG-NLS) showed decreased Bcl-2 levels
compared to cells with overexpressed wild-type plakoglobin,
which suggests that plakoglobin may play a more direct
role in regulating the expression of apoptotic genes. More
recently, it has been shown that mouse keratinocytes
that lack endogenous plakoglobin expression are protected
from etoposide-induced apoptosis, whereas plakoglobin-
expressing keratinocytes readily undergo apoptosis upon
etoposide treatment [93]. In this study, the authors demon-
strated that plakoglobin-null keratinocytes were unable to
release cytochrome c from the mitochondria and activate
caspase 3, suggesting that plakoglobin plays a role in
regulating the apoptotic cascade. Furthermore, the mRNA
levels of the antiapoptotic protein Bcl-XL were higher in
the plakoglobin null keratinocytes, which could potentially
have prevented the translocation of cytochrome c from the
mitochondria. Finally, the expression of plakoglobin in the
null keratinocytes resulted in decreased Bcl-XL levels,caspase
3 activation, and apoptosis induction following etoposide
treatment. Taken together, these studies have demonstrated
that plakoglobin does have some role in apoptosis signalingInternational Journal of Cell Biology 7
and potentially may exert part of its tumor suppressor
activity through the modulation of apoptosis.
4.5. Plakoglobin Metastasis Suppressor Activity. As the tumor
suppressor activity of plakoglobin began to be revealed,
it soon became evident that in addition to inhibiting
the growth properties of carcinoma cell lines, plakoglobin
also plays a role in regulating the invasive and migra-
tory properties of cancer cells. The initial observation of
plakoglobin metastasis suppressor activity was documented
in human umbilical vascular endothelial cells (HUVEC),
where plakoglobin was typically associated with sites of
cell-cell contact [94]. Plakoglobin antisense oligonucleotides
increased HUVEC migration, suggesting that the loss of
plakoglobin expression led to an increased migratory phe-
notype. Concurrent with increased migration, the antisense
treated HUVEC cells also became more prone to forming
tubular structures in Matrigel, suggesting that plakoglobin
knock down also promoted angiogenesis.
Mukhina et al. [95] further detailed the metastasis
suppressor activity of plakoglobin using MCF-7 cells, which
express membrane-localized E-cadherin and plakoglobin,
and stable cell junctions. In this study, the authors treated
MCF-7 cells with human growth hormone (hGH) and
observed a downregulation of plakoglobin, a cytoplasmic
distribution of E-cadherin and an increased migratory and
invasive phenotype, which was accompanied by an increase
in matrix metalloproteinase levels. Furthermore, the authors
demonstrated that hGH-mediated invasiveness was depen-
dent on Src kinase and also showed that chemical inhibitors
of Src resulted in increased plakoglobin levels and, in turn,
decreased invasion and migration. To discern the speciﬁc
role of plakoglobin in these processes, the authors expressed
plakoglobin in the hGH-treated MCF-7 cells, which resulted
in both the decreased migration and invasiveness of these
cells [95].
Themetastasissuppressoractivityofplakoglobinhasalso
been described in bladder carcinomas, where the expression
of plakoglobin in plakoglobin null cell lines resulted not
only in decreased growth and tumorigenicity (as assessed
by colony formation in soft agar and tumor formation
in nude mice, resp.), but also in decreased invasive and
migratory capabilities of the transfectants [96]. Similarly,
knock down of plakoglobin using siRNAs resulted in the
increased tumorigenic and invasive properties of bladder
carcinoma cells relative to their plakoglobin-expressing
parental cell lines. This study further demonstrated that
plakoglobin expression did not aﬀect Wnt/β-catenin sig-
naling in these bladder carcinomas, which suggested that
plakoglobin possessed tumor and metastasis suppressor
activities independent of β-catenin.
The ability of plakoglobin to act as a metastasis sup-
pressor independent of its role in cell-cell adhesion has
been demonstrated using plakoglobin null keratinocytes
[97], which were less adherent to one another and more
migratory (as assessed by transwell migration assays). How-
ever, when wild-type plakoglobin was expressed in these
cells, they became more adherent and less migratory. Using
colloidal gold-coated coverslips, the authors were able to
assess the migratory abilities of individual cells and observed
that individual plakoglobin null keratinocytes were more
migratory than their plakoglobin-expressing counterparts.
The authors also showed that plakoglobin may regulate
single keratinocyte migration by inhibition of Src signaling,
which had been previously shown to promote migration
and invasion of mammary carcinomas by downregulation
of plakoglobin (see above [95]). These results suggested
that plakoglobin could suppress migration through the
modulation of cell-cell adhesion, as had been previously
suggested.However,todeterminewhetherplakoglobincould
have an eﬀect in migration independent of its role in cell-cell
adhesion, plakoglobin null keratinocytes were transfected
with cDNAs encoding mutant plakoglobin, missing either
its N- or C-terminus (α-catenin binding and transactivation
domain, resp.). The expression of either of these mutant pro-
teins resulted in increased keratinocyte adhesiveness when
compared to the plakoglobin null cells, demonstrating that
these domains were dispensable for the adhesive function of
plakoglobin. Importantly, the authors showed that whereas
individual keratinocytes expressing the N-terminal-deleted
plakoglobin were not migratory, those that expressed the C-
terminal-deleted plakoglobin were migratory. This showed
that plakoglobin could indeed suppress migration indepen-
dent of its adhesive function (since keratinocytes expressing
C-terminal-deleted plakoglobin were as adhesive to one
another as wild-type plakoglobin expressing keratinocytes).
Subsequent work using these plakoglobin null keratinocytes
has suggested that plakoglobin aﬀected individual cell motil-
ity by regulating the deposition of the extracellular matrix
(ECM) protein ﬁbronectin, actin cytoskeleton organization
(which in turn regulates Src signaling), and RhoGTPases
[98]. Collectively, these observations clearly demonstrate
tumor/metastasis suppressor activity of plakoglobin inde-
pendent of its role in cell-to-cell adhesion.
5.Plakoglobin Functions:Regulation of
GeneExpression
When discussing roles for plakoglobin during tumorigenesis
and metastasis, it is important to consider that while
plakoglobin may function as both a regulator of cell-cell
adhesion and an intracellular signaling molecule, it may
also play a more active role in these processes through
the regulation of gene expression. Evidence supporting the
plakoglobin-mediated regulation of gene expression has
started to emerge, and work from several groups, including
ours, has suggested that plakoglobin can regulate the expres-
sion of genes involved in cell-cycle control, apoptosis, cell
proliferation, and invasion.
Williamson et al. [99] have shown that plakoglobin acts
as a repressor of the c-Myc gene. Using mouse keratinocytes
and reporter assays, the authors of this study showed
that plakoglobin suppressed c-Myc expression in a Lef-
1-dependent manner, suggesting that when plakoglobin
interacted with Lef-1, this complex was unable to promote
gene expression. These ﬁndings conﬁrmed previous results
demonstrating the ineﬃciency of these complexes in binding8 International Journal of Cell Biology
DNA [62–64, 100]. This study further showed that the
plakoglobin-mediated suppression was similar in both wild-
type and β-catenin null keratinocytes, demonstrating that
plakoglobin could regulate gene expression independent of
β-catenin. Finally, using chromatin immunoprecipitation
with plakoglobin antibodies, the authors demonstrated that
plakoglobin and Lef-1 associated with the c-Myc promoter
in keratinocytes undergoing growth arrest, which implicated
the downregulation of c-Myc gene expression as a possible
reason for the suppression of cell growth by plakoglobin.
Plakoglobin-mediated regulation of gene expression has
also been shown in renal carcinoma cells. Shtutman et al.
[101] found that the exogenous expression of plakoglobin
in cells lacking both β-catenin and plakoglobin resulted
in the increased expression of the tumor suppressor gene
PML, a nuclear protein that forms nuclear bodies and is
involved in the regulation of p53 activity. Importantly, the
increased PML levels due to plakoglobin expression were
independent of β-catenin and Tcf, since β-catenin was not
detected in the plakoglobin-expressing cells and the deletion
of Tcf/Lef sites in the PML promoter did not aﬀect the ability
of plakoglobin to increase PML gene expression. Together,
these observations suggest that plakoglobin may regulate
gene expression independent of Tcf/Lef.
In β-catenin null mesothelioma and colon carcinoma
cells, Wnt3a stimulation led to the nuclear accumulation of
plakoglobin and induced the expression of the antiapoptotic
gene Survivin [85]. Coimmunoprecipitation and chromatin
immunoprecipitation showed that plakoglobin formed a
transcriptional complex with both Tcf and the histone
acetyltransferase CBP and that this complex was associated
with the Survivin promoter [85]. While this study clearly
demonstrated that plakoglobin was capable of regulating β-
catenin target genes in a β-catenin null background, it is
again of importance to emphasize that β-catenin null tumors
are very rare and that the plakoglobin-mediated regulation
of gene expression occurs mainly in the presence of cellular
β-catenin.
As previously discussed, Todorovi´ c etal.[98] haveshown
that plakoglobin can regulate cell motility by regulating
Fibronectin and Rho-dependent Src signaling. This study
also demonstrated that plakoglobin expression resulted in
increased levels of Fibronectin mRNA without increasing
expression from the Fibronectin promoter. However, by
using Actinomycin D to inhibit transcription, the authors
were able to demonstrate that plakoglobin expression led
to the increased stability of Fibronectin mRNA, suggesting
that in addition to its role in regulating gene expression at
the level of transcription, plakoglobin may also regulate gene
expression posttranscriptionally. However, the mechanisms
underlying this action remain unclear. Overall, these studies
suggest that plakoglobin regulates gene expression at the
transcriptional and potentially at posttranscriptional levels.
6. Plakoglobin ExpressioninHumanTumors
The initial characterization of JUP, the gene encoding
plakoglobin, mapped the gene to chromosome 17q21, prox-
imal to the BRCA1 gene [102]. In this study, the authors
also analyzed RNA isolated from ovarian and breast cancer
tumors and showed that loss of heterozygosity in these
tumors and low-frequency mutations in the plakoglobin
gene predisposed patients to familial breast and ovarian
cancer. Since then, several groups have observed the loss
of plakoglobin expression in a wide range of tumors,
with the majority of these studies examining plakoglobin
in conjunction with other adhesive junctional proteins.
These studies have demonstrated that loss of plakoglobin
expressioninconjunctionwiththelackofexpressionofother
cell-cell adhesion proteins such as E-cadherin, α-catenin, β-
catenin, desmoglein, or desmoplakin resulted in increased
tumor formation and size and was correlated with increased
tumor stage, poor patient survival, and increased metastasis
in bladder, pituitary, oral, pharyngeal, skin, prostate, and
NSCLC tumors [103–111]. However, several studies have
found that decreased levels of plakoglobin alone also occur
in various tumors.
The loss of plakoglobin expression has been observed
in melanocytic and thyroid tumors [112, 113]. Cerrato et
al. [113] found that nearly 90% of papillary and follicular
tumors showed decreased or loss of membrane plakoglobin
localization. Decreased expression of the plakoglobin gene
was also observed in prostate tumors, where methylation of
the plakoglobin gene is prevalent in localized prostate cancer
when compared to benign prostatic hyperplasia, suggesting
that loss of plakoglobin expression was an early step in
prostate tumorigenesis [89]. In oropharynx squamous cell
carcinomas, decreased plakoglobin expression as well as
its abnormal cytoplasmic distribution was correlated with
increased tumor size and poor clinical outcome [114].
Incoloncarcinomas,Lifschitz-Merceretal.[115]showed
that β-catenin accumulated in the nuclei of cells of pri-
mary and metastatic adenocarcinoma and adenoma lesions,
while the levels of nuclear plakoglobin were decreased in
these tumors, suggesting that nuclear plakoglobin did not
promote tumorigenesis in the colon. In esophageal cancers,
while decreased levels of E-cadherin and plakoglobin were
associated with poor diﬀerentiation and decreased patient
survival, reduced plakoglobin levels alone correlated with
lymph node metastasis [116]. The ﬁnding that reduced
plakoglobin levels alone correlated with increased metastasis
was not limited to esophageal tumors. In renal carcinomas,
decreased plakoglobin levels have been associated with
metastasis, and patients with tumors expressing plakoglobin
showed signiﬁcantly higher survival rates than those that
did not [117]. Aberrant or decreased plakoglobin levels
have also been reported in Wilms’ tumors and soft tissue
sarcomas, where the decrease in plakoglobin was associ-
ated with increased risk of pulmonary metastasis [118,
119]. In endometrial tumors, the aberrant expression of
plakoglobin was correlated with myometrial invasion [120],
whereas medulloblastoma tumors expressing plakoglobin
were nonmetastatic, with no evidence of subarachnoid or
hematogenousmetastasis[121].Finally,reducedplakoglobin
expression was also correlated with increased lymph node
m e t a s t a s i si no r a ls q u a m o u sc e l la n db l a d d e rt u m o r s[ 122,
123]. Collectively, these observations suggest that lack or
decreased expression of plakoglobin due to genetic orInternational Journal of Cell Biology 9
epigenetic causes in tumors of diﬀerent origins is associated
with poor clinical outcome and increased tumor formation
and metastasis.
7. Growth/MetastasisInhibitory
Activitiesof Plakoglobin viaRegulation
of Gene Expression
We have developed two experimental model systems using
squamousandbreastcarcinomacelllineswithnoorverylow
plakoglobin expression and various degrees of transforma-
tion/invasiveness to speciﬁcally assess the growth/metastasis
inhibitory activities of plakoglobin. Using a combination
of molecular and cell biological approaches, including
proteomics and transcriptome analysis, we compared the
protein and mRNA proﬁles of plakoglobin-deﬁcient and
plakoglobin-expressing cell lines and their in vitro migration
and invasiveness. These analyses led to the identiﬁcation
of several growth regulatory genes that were diﬀerentially
expressed in plakoglobin-expressing transfectants compared
to their plakoglobin-deﬁcient parental cells.
Comparisonoftheproteomicproﬁlesofplakoglobinnull
SCC9 cells and their plakoglobin-expressing transfectants
allowed us to identify several tumor/metastasis regulating
proteins, which were diﬀerentially expressed in plakoglobin-
expressing transfectants (SCC9-PG-WT) relative to parental
SCC9 cells. We performed RNA microarray experiments
to determine whether changes in gene expression upon
plakoglobin expression accompanied these changes in pro-
tein levels and compared the transcriptome proﬁles of SCC9
cellsandSCC9-PG-WTtransfectants.Furthermore,todeter-
mine whether the subcellular distribution of plakoglobin
had an eﬀect on gene expression, we also compared the
RNA proﬁles of SCC9 and SCC9-PG-WT cells with those
of SCC9 cells transfected either with cDNAs-encoding
plakoglobin fused with a nuclear localization signal (NLS)
to express plakoglobin exclusively in the nucleus (SCC9-PG-
NLS), or cDNAs-encoding plakoglobin fused with a nuclear
export signal (NES) to express plakoglobin exclusively in
the cytoplasm (SCC9-PG-NES). From these experiments,
we identiﬁed three subsets of genes that were diﬀerentially
expressed based on plakoglobin expression and its subcellu-
lar distribution: those whose diﬀerential expression required
exclusively cytoplasmic plakoglobin, those whose diﬀerential
expression required nuclear plakoglobin, and those whose
diﬀerential expression required the ability of plakoglobin
to shuttle between the nucleus and the cytoplasm. Based
on the results of these experiments and analysis of the
expression patterns of plakoglobin-target genes in relation
to plakoglobin subcellular distribution, we propose that
plakoglobincanregulategeneexpressionbythreeconcurrent
mechanisms (Figure 3).
The ﬁrst of these mechanisms involves the action of
plakoglobin in the cytoplasm, where it would sequester
a protein involved in the regulation of gene expression.
In this case, plakoglobin would prevent an inhibitor of
a tumor suppressor gene or a promoter of an oncogenic
genefromenteringthenucleusandaﬀectinggeneexpression.
Plakoglobin target genes whose expression patterns were
similar in SCC9-PG-WT and SCC9-PG-NES cells and were
opposite to SCC9-PG-NLS cells would be considered part of
this group.
The second mechanism involves nuclear localized
plakoglobin, which would directly associate with a nuclear
factor and regulate gene expression. In this case, plakoglobin
would interact with a transcriptional activator and promote
gene expression, or, conversely, it would interact with
a transcriptional repressor and silence gene expression.
Plakoglobin target genes whose expression patterns were
similar in SCC9-PG-WT and SCC9-PG-NLS cells and were
opposite to SCC9-PG-NES cells would be considered part of
this group.
The vast majority of plakoglobin target genes, however,
belongedtothethirdgroupofgenes:thosewhosediﬀerential
expression depended on the ability of plakoglobin to shuttle
between the nucleus and the cytoplasm. In this case,
plakoglobin would interact with some cytoplasmic cofactor,
translocate into the nucleus, and regulate gene expression.
Plakoglobin target genes whose expression patterns were
similar in SCC9-PG-NES and SCC9-PG-NLS cells and were
opposite to SCC9-PG-WT cells would be considered part of
this group.
Following these proteomics and microarray analyses, we
began our initial characterization of the regulation of poten-
tial target genes by plakoglobin. We have recently shown
that plakoglobin expression in SCC9 cells resulted in the
increased expression of the metastasis suppressors Nm23-
H1 and -H2, both at the mRNA and protein levels [124].
Nm23 was the ﬁrst metastasis suppressor identiﬁed, as it is
often downregulated in metastatic tumors and its expression
in invasive cell lines resulted in decreased migration and
invasion (for review, see [125, 126]). We have observed that
plakoglobininteractedwithNm23-H1and-H2insquamous
cell, mammary, renal, and colon epithelial cell lines with
the colocalization of these two proteins at sites of cell-
cell contact. We have also shown that these interactions
occurred in both the cytoskeleton-associated and soluble
pool of proteins, suggesting that these interactions have
both adhesive and nonadhesive functions. Since plakoglobin
was detected in the nucleus of plakoglobin-expressing SCC9
cells and since luciferase reporter assays have shown that β-
catenin/Wnt signaling is not activated in SCC9 cells [65],
these results together suggested that plakoglobin regulates
gene expression in SCC9 cells independent of β-catenin.
We are currently characterizing whether plakoglobin directly
regulates Nm23 expression. Furthermore, we have also
shown that plakoglobin interacts with the transcription
factor p53 and regulates the expression of a number of p53
target genes (manuscript in preparation).
8. Concluding Remarks
Recent work has demonstrated that plakoglobin has novel
roles in intracellular signaling and the regulation of gene
expression, in addition to its previously well-established
roles in cell-cell adhesion. Plakoglobin has emerged as a
tumor/metastasissuppressorproteinbasedonevidencefrom10 International Journal of Cell Biology
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Figure 3: A potential model for regulation of gene expression by plakoglobin. Three concurrent mechanisms by which plakoglobin may
regulategeneexpressionareproposed.(A)Cytoplasmicsequestration:plakoglobinsequestersafactorinthecytoplasmwhich,inthenucleus,
suppresses the expression of a tumor suppressor gene or activates the expression of an oncogene. (B) Cytoplasmic cofactor independent:
plakoglobin-transcription factor complexes promote the expression of tumor suppressor genes and repress the expression of oncogenes.
(C) Cytoplasmic cofactor dependent: plakoglobin interacts with a cytoplasmic cofactor and this complex moves into the nucleus where it
activates tumor suppressor gene expression or represses oncogenic gene expression. PG: plakoglobin; TF: transcription factor.
the great majority of the studies that have examined its
signaling function. As more work focuses on the role of
plakoglobin in tumorigenesis and metastasis, it is becoming
clear that plakoglobin is a key, important player in these
processes and consequently may be a useful therapeutic
target in the treatment of cancer.
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